| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | RSS | TABLE OF CONTENTS |
|
|
|
||||||||
|
||||||||||
Basic Science Investigations |
1 Department of Nuclear Medicine, University Hospital Dresden, Dresden, Germany
2 Nuclear Medicine Group, Oak Ridge National Laboratory, Oak Ridge, Tennessee
188Re-Hydroxyethylidene diphosphonate (188Re-HEDP) was used in previous studies for the palliative treatment of metastatic bone pain. However, the kinetic and radiation-absorbed doses have not been well documented. Therefore, the aim of this study was to gather dosimetric data for 188Re-HEDP. Methods: Thirteen prostate cancer patients with skeletal involvement were treated with 2,700–3,459 MBq (mean dose, 3,120 MBq) 188Re-HEDP. Patients underwent whole-body scans 3, 20, and 28 h after therapy. The effective half-life, residence time, and radiation-absorbed dose values were calculated for the whole body, bone marrow, kidneys, and bladder as well as for 29 bone metastases. The urinary excretion rate was determined in 6 urine samples of each patient collected over 48 h at 8-h intervals beginning immediately after the administration of 188Re-HEDP. After injection of 188Re-HEDP, blood samples were taken weekly for 6 wk, and platelet and leukocyte counts were performed. Results: The mean effective half-life was 15.9 ± 3.5 h in bone metastases, 10.9 ± 2.1 h in the bone marrow, 11.6 ± 2.1 h in the whole body, 12.7 ± 2.2 h in the kidneys, and 7.7 ± 3.4 h in the bladder. The following radiation-absorbed doses were calculated: 3.83 ± 2.01 mGy/MBq for bone metastases, 0.61 ± 0.21 mGy/MBq for the bone marrow, 0.07 ± 0.02 mGy/MBq for the whole body, 0.71 ± 0.22 mGy/MBq for the kidneys, and 0.99 ± 0.18 mGy/MBq for the bladder. 188Re-HEDP showed a rapid urinary excretion within the first 8 h after therapy, with 41% of the 188Re-HEDP administered being excreted. Forty-eight hours after therapy, the excretion rate was 60% ± 12%. Only 1 patient showed a decrease of platelet count below 100 x 109 counts/L. None of the patients presented with a decrease of leukocyte count below 3.0 x 109 counts/L. Conclusion: 188Re-HEDP is an effective radiopharmaceutical used in the palliative treatment of metastatic bone pain. The radiation-absorbed dose is acceptable for bone pain palliation with low doses for the normal bone marrow and the whole body.
Key Words: radiation-absorbed dose • kinetics • 188Re-hydroxyethylidene diphosphonate • bone metastases
This article has been cited by other articles:
|
|
 |
|
  K. Liepe, C. Brogsitter, J. Leonhard, G. Wunderlich, R. Hliscs, J. Pinkert, G. Folprecht, and J. Kotzerke Feasibility of High Activity Rhenium-188-Microsphere in Hepatic Radioembolization Jpn. J. Clin. Oncol., December 19, 2007; (2007) hym137v1. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. B. Breitz, R. E. Wendt III, M. S. Stabin, S. Shen, W. D. Erwin, J. G. Rajendran, J. F. Eary, L. Durack, E. Delpassand, W. Martin, et al. 166Ho-DOTMP Radiation-Absorbed Dose Estimation for Skeletal Targeted Radiotherapy J. Nucl. Med., March 1, 2006; 47(3): 534 - 542. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Liepe, R. Runge, and J. Kotzerke Systemic radionuclide therapy in pain palliation American Journal of Hospice and Palliative Medicine, November 1, 2005; 22(6): 457 - 464. [Abstract] [PDF]
|
|
|
|
|
|
K. Liepe, J. Kotzerke, and B. Lambert Advantage of 188Re-Radiopharmaceuticals in Hepatocellular Cancer and Liver Metastases J. Nucl. Med., August 1, 2005; 46(8): 1407 - 1408. [Full Text] [PDF]
|
|
|
|
|
|
V. J. Lewington Bone-Seeking Radionuclides For Therapy J. Nucl. Med., January 1, 2005; 46(1_suppl): 38S - 47S. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | RSS | TABLE OF CONTENTS |
| JOURNAL OF NUCLEAR MEDICINE TECHNOLOGY | THE JOURNAL OF NUCLEAR MEDICINE |
